Ernexa Therapeutics Inc.

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

ERNA$2.01-2.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

	Three months ended September 30,		Nine months ended September 30,
	2026	2025	2026	2025
Operating expenses:
Research and development	$1,871	$1,035	$6,578	$3,480
General and administrative	1,119	958	4,132	3,745
Impairment of goodwill	-	-	2,044	-
Total operating expenses	2,990	1,993	12,754	7,225
Loss from operations	(2,990)	(1,993)	(12,754)	(7,225)
Other income (expense), net:
Forward sales contract expense	-	-	-	(5,847)
Change in fair value of warrant liabilities	-	-	-	1
Interest income (expense), net	49	31	148	36
Gain on extinguishment of contingent liability	-	-	41	-
Gain on extinguishment of debt	-	734	-	734
Other income (expense), net	-	(6)	69	(264)
Total other income (expense), net	49	759	258	(5,340)
Loss before income taxes	(2,941)	(1,234)	(12,496)	(12,565)
Benefit (provision) for income taxes	-	(6)	40	(17)
Net loss	(2,941)	(1,240)	(12,456)	(12,582)
Series A preferred stock dividend	-	-	(8)	(8)
Net loss attributable to common stockholders	$(2,941)	$(1,240)	$(12,464)	$(12,590)
Net loss per common share - basic and diluted	$(1.89)	$(3.77)	$(10.97)	$(56.21)
Weighted average shares outstanding - basic and diluted	1,560	329	1,136	224

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.